Update on the Natural History and Systemic Treatment of Psoriasis

Advances in Dermatology

Volumn 24, Issue C, 2008, Pages 171-196

  Richardson, Stephen K ^a   Gelfand, Joel M ^b  

^a FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGICAL AGENT; TUMOR NECROSIS FACTOR ALPHA;

DRUG ANTAGONISM; HUMAN; PSORIASIS; REVIEW; RISK FACTOR;

DERMATOLOGIC AGENTS; HUMANS; PSORIASIS; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 56349134469     PISSN: 08820880     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yadr.2008.09.006     Document Type: Review

References (134)

1. Liu Y., and Bowcock K.J. Psoriasis: genetic associations and immune system changes. Genes Immun 8 (2007) 1-12
2. Lowes M.A., Bowcock A.M., and Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 445 (2007) 866-873
3. Griffiths C.E., and Barker J.N. Pathogenesis and clinical features of psoriasis. Lancet 370 (2007) 263-271
4. Elder J.T., Nair R.P., Henseler T., et al. The genetics of psoriasis 2001: the odyssey continues. Arch Dermatol 137 (2001) 1447-1454
5. Gottlieb S.L., Gilleaudeau P., Johnson R., et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1 5 (1995) 442-447
6. Abrams Jr. L.M., Guzzo C.A., Jegasothy B.V., et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103 9 (1999) 1243-1252
7. Wrone-Smith T., and Nickoloff B.J. Dermal injection of immunocytes induces psoriasis. J Clin Invest 98 1878-87 (1996)
8. Wang F L.E., Lowes M.A., Haider A.S., et al. Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: gene regulation and cellular effect. J Invest Dermatol 2006 7 (2006) 1590-1599
9. Lee E., TW, Oestreicher J.L., et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199 1 (2004) 125-130
10. Creamer D., Allen M., Jaggar R., et al. Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol 138 (2002) 791-796
11. Krueger J.G., Krane J.F., Carter D.M., et al. Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. J Invest Dermatol 94 (1990) 135s-140s
12. Trembath R.C., Clough R.L., Rosbotham J.L., et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 6 (1997) 813-820
13. Gladman D.D., Anhorn K.A., Schachter R.K., et al. HLA antigens in psoriatic arthritis. J Rheumatol 13 3 (1986) 586-592
14. Valdimarsson H. The genetic basis of psoriasis. Clin Dermatol 25 6 (2007) 563-567
15. Rahman P., and Elder J.T. Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 64 Suppl 2 (2005) 37-39
16. Setty A.R., Curhan G., and Choi H.K. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 167 15 (2007) 1670-1675
17. Setty A.R., Curhan G., and Choi H.K. Smoking and the risk of psoriasis in women: Nurses' Health Study II. Am J Med 120 (2007) 953-959
18. Naldi L., Chatenoud L., Linder D., et al. Shin DB Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 125 (2005) 61-67
19. Neimann A.L., Shin D.B., Wang X., et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55 5 (2006) 829-835
20. Karason A., Gudjonsson J.E., Upmanyu R., et al. A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting. Am J Hum Genet 72 1 (2003) 125-131
21. Lee F.I., Bellary S.V., and Francis C. Increased occurrence of psoriasis in patients with Crohn's disease and their relatives. Am J Gastroenterol 85 (1990) 962-963
22. Gottlieb A.B., Chao C., and Dann F. Psoriasis comorbidities. J Dermatolog Treat 19 (2008) 5-21
23. Kurd S.K., Richardson S.K., and Gelfand J.M. Update on the epidemiology and systemic treatment of psoriasis. Expert Review of Clinical Immunology 3 (2007) 171-185
24. Horn E.J., Fox K.M., Patel V., et al. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol 57 (2007) 963-971
25. Gelfand J.M., Gladmann D.D., Mease P.J., et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 53 (2005) 573-577
26. Cohen M.R., Reda D.J., and Clegg D.O. Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies. J Rheumatol 26 1752-1756 (1999)
27. Gladman D.D., Shuckett R., Russell M.L., et al. Psoriatic arthritis (PSA) - an analysis of 220 patients. QJM 62 (1987) 127-141
28. Wong K., Gladman D.D., Husted J., et al. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. Causes and risk of death. Arthritis Rheum 40 (1997) 1868-1872
29. Shbeeb M., Uramoto K.M., Gibson L.E., et al. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. J Rheumatol 27 (2000) 1247-1250
30. Gladman D.D., Farewell V.T., and Nadeau C. Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. J Rheumatol 4 (1995) 675-679
31. McDonald C.J., and Calabresi P. Occlusive vascular disease in psoriatic patients. N Engl J Med 288 (1973) 912
32. Gelfand J.M., Niemann A., Shin D.B., et al. Risk of myocardial infarction in patients with psoriasis. JAMA 296 14 (2006) 1735-1741
33. Ludwig R., Herzog C., Rostock A., et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 156 2 (2006) 271-276
34. Cohen A.D., Sherf M., Vidavsky L., et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 216 (2008) 152-155
35. Paul C.F., Ho V.C., McGeown C., et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 120 2 (2003) 211-216
36. Stern R.S., and Vakeva L.H. Noncutaneous malignant tumors in the PUVA follow-up study: 1975-1996. J Invest Dermatol 108 6 (1997) 897-900
37. Hannuksela-Svahn A., Sigurgeirsson B., Pukkala E., et al. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. Br J Dermatol 141 3 (1999) 497-501
38. Frentz G., Olsen J.H., and Avrach W.W. Malignant tumours and psoriasis: climatotherapy at the dead sea. Br J Dermatol 141 6 (1999) 1088-1091
39. Boffetta P., Gridley G., and Lindelof B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 117 6 (2001) 1531-1537
40. Hannuksela-Svahn A., Pukkala E., Laara E., et al. Psoriasis, its treatment, and cancer in a cohort of Finnish patients. J Invest Dermatol 114 3 (2000) 587-590
41. Frentz G., and Olsen J.H. Malignant tumours and psoriasis: a follow-up study. Br J Dermatol 140 2 (1999) 237-242
42. Gelfand J.M., Shin D.B., Neimann A.L., et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 126 10 (2006) 2194-2201
43. Stern R.S. Lymphoma risk in psoriasis: results of the PUVA follow-up study. Arch Dermatol 142 9 (2006) 1132-1135
44. Gupta M.A., and Gupta A.K. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 139 5 (1998) 846-850
45. Gupta M.A., Schork N.J., Gupta A.K., et al. Suicidal ideation in psoriasis. Int J Dermatol 32 3 (1993) 188-190
46. Polenghi M.M., Molinari E., Gala C., et al. Experience with psoriasis in a psychosomatic dermatology clinic. Acta Derm Venereol Suppl (Stockh) 186 (1994) 65-66
47. Gupta M.A., Gupta A.K., and Haberman H.F. Psoriasis and psychiatry: an update. Gen Hosp Psychiatry 9 3 (1987) 157-166
48. Rubino I.A., Sonnino A., Pezzarossa B., et al. Personality disorders and psychiatric symptoms in psoriasis. Psychol Rep 77 2 (1995) 547-553
49. Vidoni D., Campiutti E., D'Aronco R., et al. Psoriasis and alexithymia. Acta Derm Venereol Suppl (Stockh) 146 (1989) 91-92
50. Gupta M.A., Gupta A.K., and Watteel G.N. Early onset (< 40 years age) psoriasis is comorbid with greater psychopathology than late onset psoriasis: a study of 137 patients. Acta Derm Venereol 76 6 (1996) 464-466
51. Richards H.L., Fortune D.G., Weidmann A., et al. Detection of psychological distress in patients with psoriasis: low consensus between dermatologist and patient. Br J Dermatol 151 6 (2004) 1227-1233
52. Ginsburg I.H., and Link B.G. Feelings of stigmatization in patients with psoriasis. J Am Acad Dermatol 20 1 (1989) 53-63
53. Devrimci-Ozguven H., Kundakci T.N., Kumbasar H., et al. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol 14 4 (2000) 267-271
54. Fortune D.G., Richards H.L., Kirby B., et al. Psychological distress impairs clearance of psoriasis in patients treated with photochemotherapy. Arch Dermatol 139 6 (2003) 752-756
55. Tyring S., Gottlieb A., Papp K., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367 (2006) 29-35
56. Kimball A.B., Gladman D., Gelfand J.M., et al. Psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 58 6 (2008) 1031-1042
57. Gelfand J.M., Troxel A.B., Lewis J.D., et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 143 12 (2007) 1493-1499
58. Pariser D.M., Bagel J., Gelfand J.M., et al. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol 143 (2007) 239-242
59. Springer T.A. Adhesion receptors of the immune system. Nature 346 6283 (1990) 425-434
60. Gottlieb A.B., Masud S., Ramamurthi R., et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-alpha monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. J Am Acad Dermatol 48 1 (2003) 68-75
61. Hancock G.E., Kaplan G., and Cohn Z.A. Keratinocyte growth regulation by the products of immune cells. J Exp Med 168 4 (1988) 1395-1402
62. (adalimumab) Humira. Package insert (2008), Abbott Laboraties, North Chicago
63. Gordon K.B., Langley R.G., Leonardi C., et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 55 4 (2006) 598-606
64. Reich K., Nestle F.O., Papp K., et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366 9494 (2005) 1367-1374
65. Baert F., Norman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. NEJM 348 (2003) 601-608
66. Menter A., Feldman S.R., Weinstein G.D., et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 56 (2006) 31.e1-31.e15
67. Moreland L.W., Schiff M.H., Baumgartner S.W., et al. Etancercept therapy in rheumatoid arthritis: a randomized, controlled trial. Ann Intern Med 130 6 (1999) 478-486
68. Zhou H., Mayer P.R., Wajdula J., et al. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. J Clin Pharmacol 44 11 (2004) 1235-1243
69. Clark L., and Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol 58 (2008) 443-446
70. Shen C., Assche G.V., Colpaert S., et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 21 (2005) 251-258
71. Wallis R.S., and Ehlers S. Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Semin Arthritis Rheum 34 5 Suppl 1 (2005) 34-38
72. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ?. Semin Arthritis Rheum 34 5 Suppl. 1 (2005) 12-18
73. Haider A.S., Cardinale I.R., Whynot J.A., et al. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes. J Investig Dermatol Symp Proc 12 (2007) 9-15
74. Rutgeerts P., D'Haens G., Targan S., et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117 (1999) 761-769
75. Sandborn W.J., Hanauer S.B., Katz S., et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121 (2001) 1088-1094
76. Hanauer S.B., Sandborn W.J., Rutgeerts P., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130 (2006) 323-333
77. Chung E.S., Packer M., Lo K.H., et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-a in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107 (2003) 3133-3140
78. Centocor. Remicade (Inflximab) prescribing information. Malvern PU (2006)
79. Mease P.J., Ritchlin C.T., Martin R.W., et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 31 (2004) 1356-1361
80. Fomin I., Caspi D., Levy V., et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blocker. Ann Rheum Dis 65 (2006) 191-194
81. Geborek P, Bladstrom A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis;64:699-703.
82. Wolfe F., and Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50 (2004) 1741-1751
83. Wolfe F., and Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 56 (2007) 1433-1439
84. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
85. Wolfe F., and Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 56 (2007) 2886-2895
86. Stone J.H., Holbrook J.T., Marriott M.A., et al. Wegener's Granulomatosis Etanercept Trial Research Group. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 54 (2006) 1608-1618
87. Magliocco M.A., and Gottlieb A.B. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. J Am Acad Dermatol 51 4 (2004) 580-584
88. Aslanidis S., Vassiliadis T., Pyrpasopoulou A., et al. Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 26 2 (2007) 61-264
89. Bellisai F., Giannitti C., Donvito A., et al. Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection. Clin Rheumatol 26 7 (2007) 1127-1129
90. Parke F.A., and Reveille J.D. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 51 (2004) 800-804
91. Zein N.N., and Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 42 (2005) 315-322
92. Nathan D.M., Angus P.W., and Gibson P.R. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 21 9 (2006) 1366-1371
93. Roux C.H., Brocq O., Breuil V., et al. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology 45 (2006) 1294-1297
94. Theis V.S., and Rhodes J.M. Review article: minimizing tuberculosis during anti-tumor necrosis factor-alpha treatment of inflammatory bowel disease. Ailment Pharmacol Ther 27 (2008) 19-30
95. Lebwohl M., Bagel J., Gelfand J.M., et al. From the medical board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol 58 (2008) 94-105
96. Hochberg M.C., Lebwohl M.G., Plevy S.E., et al. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 34 (2005) 819-836
97. CDC Morbidity and Mortality Week Report. Targeted tuberculin testing and treatment of latent tuberculosis infection 2000;49(RR06):1-54.
98. CDC Morbidity and Mortality Week Report. Guidelines for using the QuantiFERON-TB Test for diagnosing latent mycobacterial tuberculosis infection 2003;52(RR02):15-8.
99. Perez J.L., Kupper H., and Spencer-Green G.T. Impact of screening for latent TB prior to initiation of anti-TNF therapy in North America and Europe. Ann Rheum Dis 64 Suppl. III (2006) 86A
100. Sichletidis L., Settas L., Spyratos D., et al. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 10 (2006) 1127-1132
101. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53 (1999) 457-465
102. Codoro K.M., and Feldman S.R. TNF-a inhibitors in dermatology. Skin Therapy Lett 12 (2007)
103. (efalizumab) Raptiva. Package insert (2007), Genentech, Inc., South San Francisco (CA)
104. Ellis C.N., and Krueger G.G. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345 4 (2001) 248-255
105. Cooper J.C., Morgan G., Harding S., et al. Alefacept selectively promotes NK cell-mediated deletion of CD45RO+ human T cells. Eur J Immunol 33 3 (2003) 666-675
106. Haider A.S., Lowes M.A., Gardner H., et al. Novel insight into the agonistic mechanism of alefacept in vivo: differentially expressed genes may serve as biomarkers of response in psoriasis patients. J Immunol 178 11 (2007) 7442-7449
107. Vaishnaw A.K., and TenHoor C.N. Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. J Pharmacokinet Pharmacodyn 29 (2002) 415-426
108. Lebwohl M., Christophers E., Langley R., et al. For the Alefacept clinical study group. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139 6 (2003) 719-727
109. Gribetz C.H., Blum R., Brady C., et al. An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. J Am Acad Dermatol 53 (2005) 73-75
110. Menter A., Cather J.C., Baker D., et al. The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol 54 (2006) 61-63
111. Goffe B., Papp K., Gratton D., et al. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. Clin Ther 27 (2005) 1912-1921
112. Mease P.J., Gladman D.D., and Keystone E.C. Alefacept in Psoriatic Arthritis Study Group. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 54 (2006) 1638-1645
113. Kraan M.C., van Kuijk A.W., Dinant H.J., et al. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 46 (2002) 2776-2784
114. Gordon K.B., and Langley R.G. Remittive effects of intramuscular alefacept in psoriasis. J Drugs Dermatol 2 6 (2003) 624-628
115. Amevive (alefacept) prescribing information. Biogen Inc. (Cambridge, MA) 2005.
116. Gottlieb A.B., Casale T., Frankel E., et al. CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol 49 (2003) 816-825
117. Gordon KB, Papp K.A., Hamilton T.K., et al. Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 290 23 (2003) 3073-3080
118. Raptiva (efalizumab) package insert. South San Francisco (CA): Genentech, Inc.; 2003.
119. Hamilton T.K. Clinical considerations of efalizumab therapy in patients with psoriasis. Semin Cutan Med Surg 24 (2005) 19-27
120. Cather J.C., and Menter A. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther 3 (2003) 361-370
121. Carey W., Glazer S., Gottlieb A.B., et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol 54 4 Suppl. 1 (2006) S171-S181
122. Papp K.A., Toth D., and Rosoph L. Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence. BMC Dermatol 6 (2006) 9
123. Krueger J., Ochs H., Patel P., et al. Impact of efalizumab T cell modulation on immune response in psoriasis patients. J Investig Dermatol 124 Suppl. 4 (2005) 264
124. Robertson M.J., and Ritz J. Interleukin 12: basic biology and potential application in cancer treatment. Oncologist 1 (1996) 88-97
125. Aggarwal S., Ghilardi N., Xie M.H., et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 278 (2003) 1910
126. Kuligowska M., and Odrowaz-Sypniewska G. Role of interleukin-17 in cartilage and bone destruction in rheumatoid arthritis. Ortop Traumatol Rehabil 6 2 (2004) 235-241
127. Nograles K.E., Zaba L.C., Guttman-Yassky E., et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol Aug 5 (2008) [Epub ahead of print]
128. Torti D.C., and Feldman S.R. Interleukin-12, interleukin-23 and psoriasis: current prospects. J Am Acad Dermatol 57 6 (2007) 1059-1068
129. Krueger J.G., Langley R.G., Leonardi C., et al. Psoriasis Study Group. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356 6 (2007) 580-592
130. Papp K.A., Langley R.G., Lebwohl M., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371 9625 (2008) 1675-1684
131. Leonardi C.L., Kimball A.B., Papp K.A., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371 9625 (2008) 1665-1674
132. Sandborn W.J. How future tumor necrosis factor antagonists and other compounds will meet the remaining challenges in Crohn's disease. Rev Gastroenterol Disord 4 Suppl (2004) S25-S33
133. Kimball A.B., Gordon K.B., Langley R.G., et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 144 (2008) 200-207
134. Menter A., Tyring S.K., Gordon K., et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 58 (2007) 106-115